The stories about Pharmos and dexanabinol in relation to TBI is worth a read. Although they ultimately failed as could Neuren, the potential upside is enormous.
Think that current trials must be based around dexanabinol trials.
If Neuren is on a winner and has orphan drug status for some of its products then its current market cap will become nothing more than a joke.
Did say if!
neuren signs cancer license ...., page-17
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.40 |
Change
1.130(8.52%) |
Mkt cap ! $1.840B | |||
| Open | High | Low | Value | Volume |
| $13.80 | $14.45 | $13.53 | $15.04M | 1.062M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 871 | $14.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.42 | 3650 | 3 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |